Besifloxacin ophthalmic suspension 0.6

Drugs

Volumn 70, Issue 1, 2010, Pages 83-97

  Carter, Natalie J ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; BESIFLOXACIN; BESIVANCE; BOL 303224 A; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SS 734; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BIOMICROSCOPY; BLURRED VISION; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DERMATITIS; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FEVER; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; IRITIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCULAR PRURITUS; PHARMACODYNAMICS; PHOTOPHOBIA; PLASMA CONCENTRATION-TIME CURVE; REVIEW; SORE THROAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS PNEUMONIAE; SUSPENSION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AZA COMPOUNDS; AZEPINES; COLONY COUNT, MICROBIAL; CONJUNCTIVITIS, BACTERIAL; DNA GYRASE; DNA TOPOISOMERASE IV; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EYE; FLUOROQUINOLONES; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; QUINOLINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUSPENSIONS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 73349089633     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203820-000000000-00000     Document Type: Review

References (30)

1. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008 Feb; 86 (1): 5-17
2. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008 Jul; 75 (7): 507-512
3. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004 Mar; 49 (2 Suppl. 2): S79-83
4. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009 May; 25 (5): 1159-1169
5. Bausch & Lomb Incorporated. Besivance™ (besifloxacin ophthalmic suspension) 0.6%: highlights of US prescribing information [online]. Available from URL: http://www.access data.fda.gov/drugsatfda-docs/label/2009/022308lbl. pdf [Accessed 2009 Nov 30]
6. Bausch & Lomb Incorporated. Besifloxacin ophthalmic suspension 0.6% (Besivance): Canadian Product Monograph. Vaughan (ON): Bausch & Lomb Incorporated, 2009 Oct 23
7. Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009; 25 (4): 1-9
8. Cambau E, Matrat S, Pan X-S, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Anti-microb Chemother 2009 Mar; 63 (3): 443-450
9. Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmaco-dynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007 Jun; 23 (3): 243-256
10. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009 Aug; 53 (8): 3552-3560
11. Haas W, Brunner LS, Pillar C, et al. Bactericidal activity of besifloxacin and other ophthalmic antibacterials against recent ocular isolates [poster no. 2675]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2009 May 3-7; Fort Lauderdale (FL)
12. Proksch JW, Chappa AK, Haas W, et al. Besifloxacin, moxifloxacin, and gatifloxacin ocular tissue AUC/MIC ratios for fluoroquinolone-resistant organisms [poster no. 0905]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2009 May 3-7; Fort Lauderdale (FL)
13. Haas W, Zurenko GE, Lee J, et al. Activity of besifloxacin and comparators against ciprofloxacin resistant Staphylococcus aureus and Staphylococcus epidermidis ocular isolates from 2005-2008 [poster]. 3rd Congress of the Federation of European Microbiologists; 2009 Jun 28-Jul 2; Gothenberg
14. Brunner LS, Norton SE, Blondeau JM. In vitro activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis [poster no. P1679]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy and Infectious Diseases; 2007 Mar 31-Apr 3; Munich
15. McDonald MB, Blondeau JM, DeCory HH, et al. Multidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitis [poster no. PO070]. Annual Meeting of the American Academy of Ophthalmology; 2008 Nov 8-11; Atlanta (GA)
16. Brunner LS, Walsh PA, Norton SE, et al. Bactericidal activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis [poster no. P1680]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy and Infectious Diseases; 2007 Mar 31-Apr 3; Munich
17. Blondeau JM, Brunner L, Norton S. In vitro activity against Gram-negative pathogens of SS734: a new fluoroquinolone (FQ) for the treatment of bacterial conjunctivitis (BC). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
18. Morris TW, Haas W, Brunner LS, et al. Clinical efficacy of besifloxacin ophthalmic suspension; integrated microbiological analysis of 3 trials for topical treatment of bacterial conjunctivitis [poster no. 5945]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2009 May 3-7; Fort Lauderdale (FL)
19. Center for Drug Evaluation and Research. Besifloxacin: microbiology review(s) [online]. Available from URL: http:// www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/022308 s000-MicroR.pdf [Accessed 2009 Nov 30]
20. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptiblity tests for bacteria that grow aerobically; approved standard, eighth edition (document M07-A8). Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Dec 30
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptiblity testing; nineteenth informational supplement (document M100-S19). Wayne (PA): Clinical and Laboratory Standards Institute, 2009; 28 (1)
22. Zhang J-Z, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 mono-cytes. J Antimicrob Chemother 2008 Jan; 61 (1): 111-116
23. Zhang J-Z, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human cor-neal epithelial cells. Curr Eye Res 2008 Nov; 33 (11): 923-932
24. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009 Sep; 116 (9): 1615-1623
25. Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009 Mar; 31 (3): 514-526
26. Comstock TL, Paterno MR, Lynch JA, et al. Efficacy and safety of besifloxacin ophthalmic suspension, 0.6% in pe-diatric patients with bacterial conjunctivitis [poster no. 2667]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2009 May 3-7; Fort Lauder-dale (FL)
27. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999 Jan; 12 (1): 147-179
28. Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalk-onium chloride compared with ciprofloxacin and levo-floxacin against methicillin-resistant Staphylococcus aur-eus. J Chemother 2007; 19 (2): 146-151
29. Hesje CK, Borsos SD, Blondeau JM. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. J Ocul Pharmacol Ther 2009; 25 (4): 329-333
30. Paterno MR, Comstock TL, Lynch JA, et al. Besifloxacin ophthalmic suspension, 0.6% is safe and well tolerated in the treatment of bacterial conjunctivitis [poster no. 2674]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 2009 May 3-7; Fort Lauderdale (FL)